Biotechnology consulting refers to the practice of organization involved in Pacificlinkconsulting services contact: San Diego, CA 92127 Phone: 858-335-1300

1. Pacific-Link Consulting
Capability Presentation
http://www.pacificlinkconsulting.com
1

2. Company Overview
Founded in 2007
Founder
Richard E. Lowenthal MS, MSEL
Sarina Tanimoto, MD, PhD
 Office
San Diego, CA
Tokyo, Japan
London, UK (Partner, Sirius Consulting)
US Employees: 16 employees
2

3. Services
Comprehensive Therapeutic Product
Development Consulting (US/EU/Japan)
Regulatory Affairs and Quality Assurance
Auditing and Quality Management
Clinical and Pharmaceutical
Development
Biostatistics
Medical / Technical Writing
Electronic eCTD (IND/NDA/MAA)
Licensing
Due Diligence (Pharmaceutical,VC)
3

4. Consultant
Richard E. Lowenthal MS, MSEL
Main Past Positions
 FDA New Drug Reviewer
 Regulatory Affairs and Global Project Leader at Janssen
 VP of Regulatory Affairs and Quality Assurance at Somerset,
AnGes, Maxim and Cadence
 Acting Sr.Vice President at Jennerex Biotherapeutics and Auspex
 Member of the Board at Momotaro Gene since 2012 (responsible
for all US operations)
Expertise and Experiences
 Regulatory Strategy, Negotiation with Agencies
(FDA/EMEA/PMDA)
 Biologics and Drugs: FDA, EMA and NIH/RAC
 Participated in the filing and approval of 18 marketed products
4

5. Consultant
Sarina Tanimoto, MD MBA
 Main Past Positions




MD, MPH, MBA, PhD
Nippon Roche (Clinical Development)
AnGes MG (Clinical and Business Development)
Founder PLC in the US and Japan
 Expertise and Experiences
 Clinical Development and Safety Monitoring for Drug
and Biologics
 Japan MHLW Orphan Drug Designations
 PMDA Negotiations and Meetings
 Business Development in Japan and US
5

6. Pacific-Link Biologics Experts
Key PLC Experts on Biologics
 Robert Bell PhD -
Biologics Manufacturing Expert
 25 years Baxter and Barr; Member of USP Biologics Committee
 Michael Hatfield, PhD – Biotechnology Development
 Selective Genetics, Onyx, Jennerex; Extensive Analytical Expertise
 Joyce Reyes, MSc RAC – Biologics Quality and Reg.
 Invitrogen, Xoma, InterMune, Cell Genesis, Geron, Jennerex
Charles Olson, PhD – Biologics Manufacturing Expert
 Bayer, Onxy, Biomarin, Cell Genesis, NextBio
Joseph Crea – Quality Assurance Expert
 30+ years biologic qualify experience; Janssen, Iroko
Tracy Ross-Teichart, PhD - Nonclinical
6

7. Pacific-Link Key Partners
Sirius Regulatory
Consulting
EU Representative
Drug and Biotechnology
Development
Biotechnology GMP
Manufacturing
AccuReg Inc.
GCP Auditing and
Compliance
PEC and Omnicia
eCTD Software and
Filing Services
Duck Flats Pharma, Inc.
Phase I/II Specialty CRO
The Sage Group
High Level Business
Development
7

8. Key Areas of Expertise
Strategic Development for Biologics and
Pharmaceutical Products
Regulatory Interactions and Strategy for
US, Japan and EU (Global Development)
Project Management
Clinical Development and Site
Management
Business Development and Value
Maximization Strategies
Support of Due Diligence Reviews for
Companies and Venture Capital Groups
8

9. Experience
Support Multiple High Tech Companies
 Jennerex – Oncolytic Viruses
 Green Cross – Advanced Biologic Peptide
 Momotaro Gene – Viral Vaccine Therapy
 REGiMMUNE – Immune Regulatory Tehrapy
Other biologics utilizing cell based production
(NGM, Coheris, Polaris, I2O, iGM, )
Multiple Other Past and Present Clients
9

10. Biosimilar Expertise
Extensive expertise with the development
of advanced Biologic based products:
Complex proteins
Cell based therapies and production processes
Viral therapies and production processes
Regulatory experience with advanced
biologics in both CDER and CBER
10

11. EXPERIENCES
11

12. Example: Momotaro-Gene Inc.
Full Project Management Responsibilities
 Manufacturing Support in Liverpool England and Baylor
University
 Managed GLP Toxicology Studies at MPI Research
 Worked with Okayama University on Preclinical Program
 Prepare and conduct Phase I trial
FDA Interactions and Consultation
 Pre-PreIND Consultation Jan 2009 (design of Dev. Plan)
 PreIND Meeting Nov 2009 (adjust Dev. Plan and IND)
 Multiple informal discussions and consultations
NIH RAC Filed Jan 2010 : Public Meeting March 2010 :
RAC Approval March 2010
IND Filed March 1 2010 : Approved March 31
Conducting Phase I Clinical Trials in 2 indications
12

13. Example: Current Clinical Trials
Extensive Experience in Clinical Trial Management
Current Clinical Trials Under Management
 Momotaro Gene (MTG-REIC-PC001), Green Cross (MG1102-01),
REGiMMUNE (RGI-2001-02) and others
 Preparation
 Write protocol: Develop Protocol with KOLs and Pis, Negotiate Protocol with
FDA, Obtain Scientific and IRB Approvals at Sites
 Select sites: Evaluate Site qualifications, build relationship with investigators
 Create documents: IRB related, CRF
 Manage IRB Submissions and Approvals
 Site initiation
 Manage trial conduct directly through contract CRA and Data Management
 Evaluate & negotiate proposals from CRO: Develop Trial Management Plan,
Budget, Responsibilities and Compliance requirements.
 Management




Train site coordinator, monitor and pharmacy
Track enrollment
DSMB: chose members, organize charter and hold meetings
Manage conduct of CRO
13

14. PROJECT EXAMPLES
14

15. Support for Innovators
Overall Project Management
Development Plans and Regulatory Support
What quality and studies are required for IND and MA
Pharm studies, Preclinical studies (incl. Tox) and Clinical
studies, what , where and when?
Risk assessment
Obtain advice from agencies regarding studies and
quality required
→Avoid unnecessary work and focus on necessary
studies to achieve key company milestones
Manage clinical trial
Consult with Agencies in VERY early stage
15

16. Support for BioPharmaceutical Companies
Senior Level Strategic Advice and Review of
Submissions.
Long Term Regulatory Liaison
Support/Emergency Support
Support Compliance and Production Processes
Prepare Clinical/Regulatory Documents
 IND/BLA/NDA documents
 Protocols, IB, SSP
 Communication with Agencies
16

17. Support for VC
 Due Diligence
 Review Product Technical Details
 Product Risk Assessment (Probability of
Success from a Technical Perspective)
 Review Regulatory Pathway for FDA, EMA
and PMDA
 Review of Development Plan and Cost
Estimates
 Provide Strategic Advice to Venture Start-up
Companies
17

18. Quality Auditing and Management
Direct Auditing Expertise for both
Manufacturing and Clinical Sites
Richard Lowenthal formerly member of the
FDA GMP Committee during CFR 211
Rewrite of Regulations.
Expertise in GCPs and Clinical Audits
Partner Companies and Experts Available to
further Support Client Needs
Routinely Audit Biotech and Drug
Facilities
Routinely Audit Clinical Sites and Central
Labs
18

19. Support for Generic Business
Experience with Multiple ANDA Filings
and OGD procedures
Structured Templates that Meet OGD
Requirements
Relationships with OGD Staff
Capability to resolve potential issues prior to
submission
Able to negotiate critical points during review
Full Filing Capability Including Electronic
eCTD Capability
19

20. Support for US Operations
PLC routinely supports foreign
companies subcontracting in the United
States (US)
Direct supervision of contract facilities
GMP Production, GLP Nonclinical Studies
Manage CROs for Clinical Trials
PLC can subcontract to consolidate
contracting and management of US
Contractors
20

21. Safety Management
Medical Monitoring Capability
Clinical Site Management of Medical Issues
Collection of Safety Data
Central Medical Monitor Interpretation of
Events
Regulatory Reporting
 SAEs
 Annual Report
21

22. Support for Overseas companies
Overall Project Management
Development Plans and Regulatory Support
 IND – NDA/BLA – Launch
 Define what quality and studies are required each stage
 Pharm studies, Preclinical studies (incl. Tox) and Clinical studies,
what , where and when?
 Risk assessment
Product Development Support
 Select manufacturing sites and support technology transfers
 Build relationships with subcontractors
 Conduct pre-qualification audits
 Evaluated product development plans and data
 Help managed US subcontract facilities
22

23. Support for Japanese Market
Overall Project Management
Development Plans and Regulatory Support
 Orphan Drug Designation
 Asian bridging trials
 PMDA consultation for development
 IND – NDA/BLA – Launch
 Define what quality and studies are required each stage
 Pharm studies, Preclinical studies (incl. Tox) and Clinical studies
 Risk assessment
Clinical Development Support
 Select clinical sites and prepare & conduct clinical trial
 Build relationship with KOLs and investigators
 Create protocol
 Identify CRO and CRO management
 DSMB management
 Report writing
23

24. Comprehensive Service
English/Ja
panese
Capability
Low
Overhead
24

25. Thank you !
Contact
Richard Lowenthal
richard@pacificlinkconsulting.com
Sarina Tanimoto
sarina@pacificlinkconsulting.com
25